Abstract
We propose a consensus definition of “an exaggerated orthostatic pressor response” in subjects in whom systolic blood pressure increases ≥20 mmHg when going from the supine to standing posture. This definition can be extended for seated to standing measurements. We reserve the term “orthostatic hypertension” if this pressor response leads to an upright systolic blood pressure ≥140 mmHg. We believe this consensus definition will help in the study of the pathophysiology, clinical impact, and potential treatment of these entities, and the identification of patients that are at greater cardiovascular risk.
Background
Standing imposes a major hemodynamic burden on the cardiovascular system. In healthy persons, neurohumoral reflex mechanisms, particularly the arterial baroreflex, maintain blood pressure with standing. However, the counterregulatory response overshoots in some people such that blood pressure increases with standing. This orthostatic pressor response may result in hypertensive blood pressure levels only when standing or further exacerbate arterial hypertension. The condition is often referred to as orthostatic hypertension and appears to be associated with increased cardiovascular risk [1, 2]. Yet, a uniform definition and diagnostic cutoff values of orthostatic hypertension have not been established. In fact, current hypertension guidelines do not cover orthostatic hypertension [3,4,5]. Moreover, diagnostic criteria for orthostatic hypertension vary from study to study. Therefore, data regarding the prevalence, cardiovascular risk, and management of orthostatic hypertension is difficult to interpret. We propose a new classification distinguishing between an exaggerated orthostatic pressor response and orthostatic hypertension to facilitate research in this area.
Definitions
-
An exaggerated orthostatic pressor response is a sustained increase in systolic blood pressure by at least 20 mmHg when changing from the supine to the standing position regardless of absolute blood pressure while standing.
-
Orthostatic hypertension is defined as an exaggerated orthostatic pressor response associated with systolic blood pressure of at least 140 mmHg while standing.
Rationale
Our goal was to arrive at a pragmatic definition that could be utilized in the setting of mechanism-oriented studies, epidemiological surveys, and clinical trials. We are aware that the suggested definitions are based on clinical reasoning and normative data rather than cardiovascular risk estimates and that the definitions as well as blood pressure cutoff values may have to be refined in the future. While orthostatic hypertension may be associated with cardiovascular risk as outlined in the sections below, more data is required to allow for a risk-based definition.
In the Malmö Preventive Project, blood pressure measurements after 10 min in the supine position and after one-minute standing were measured in 33,346 persons aged 45.7 ± 7.4 years [6]. On average, systolic blood pressure decreased 1.2 mmHg with a standard deviation of 8.8 mmHg. In the follow-up study to the Malmö Preventive Project, the Malmö Offspring Study [7], among 4019 participants aged 41.9 ± 14.5 years, systolic blood pressure increased by 1.4 ± 8.6 mmHg after 3 min of standing corroborating Malmö Preventive Project observations. Thus, 20 mmHg systolic blood pressure cutoff value for an exaggerated orthostatic pressor response corresponds to approximately two standard deviations above the population mean.
An increase in diastolic blood pressure on standing can be normal. Moreover, in individuals with excessive orthostatic heart rate increases, cardiac stroke volume may decrease such that pulse pressure is narrowed. The resulting spurious diastolic blood pressure increase is difficult to interpret. The panel, therefore, suggests that systolic blood pressure may be more practical when diagnosing orthostatic hypertension.
A recent publication by an expert group suggested that a systolic blood pressure increase while standing by at least 20 mmHg or above 140 mmHg in otherwise normotensive persons could serve as criteria for orthostatic hypertension [8]. The limitation of this broad definition is that individuals with upright blood pressure in the normotensive range could be labeled as being “hypertensive”. Even though we cannot exclude that orthostatic blood pressure surges even within the normotensive range can have negative influences on the cardiovascular system, it appears likely that an absolute standing blood pressure in the upright posture is more relevant to cardiovascular risk. Therefore, we propose to distinguish between an exaggerated orthostatic pressor response, which may result in normotensive or hypertensive blood pressure while standing, and factual orthostatic hypertension. Among persons with orthostatic hypertension, some may exhibit isolated orthostatic hypertension, which is an orthostatic pressor with hypertensive blood pressure values only while standing. Others may also be hypertensive while supine or seated with further worsening of blood pressure when standing. Possibly, these subgroups may require a different diagnostic and therapeutic approach [2, 9].
Pathophysiology of orthostatic hypertension
With standing, approximately 500–1000 ml blood is pooled below the diaphragm and hydrostatic pressure shift fluids from the intravascular to the interstitial compartment. In healthy persons, compensatory autonomic reflex mechanisms withdraw cardiac parasympathetic drive and raise cardiac and vascular sympathetic activity thereby leading to an increase in heart rate, a drop in systolic blood pressure <20 mmHg, and a small increase in diastolic blood pressure [10, 11]. Small-scale studies suggest that orthostatic hypertension results from an excessive increase in vascular resistance with standing [12], however, the mechanisms driving orthostatic hypertension may be affected by age [13, 14]. The observations that plasma norepinephrine increases more with standing in patients with orthostatic hypertension suggest that the response is mediated through excessive sympathetic activation with standing [12, 15]. Indeed, alpha-adrenoreceptor blockade attenuates orthostatic hypertension [16]. Patients with orthostatic hypertension often feature an extreme dipping pattern in 24 h ambulatory blood pressure recordings [14], and an exaggerated early morning blood pressure surge [15].
Epidemiology and cardiovascular risks of orthostatic hypertension
The epidemiology of orthostatic hypertension and the data regarding the cardiovascular risk associated with orthostatic hypotension have been reviewed recently [1]. Briefly, orthostatic hypertension defined as a sustained increase in systolic blood pressure ≥20 mmHg and/or diastolic blood pressure ≥10 mmHg within 3 min of standing was observed in 5–30% of participants in epidemiological surveys or clinical trials [17,18,19,20,21]. Risk factors for orthostatic hypertension included age, adiposity, arterial hypertension, and diabetes mellitus [22]. An exaggerated orthostatic pressor response with office blood pressure in the normotensive range may precede arterial hypertension in younger people [23]. Among people with arterial hypertension, individuals showing an exaggerated orthostatic pressor response are more likely to exhibit subclinical cerebrovascular disease, peripheral arterial disease, or cerebrovascular disease [15, 24,25,26]. Orthostatic hypertension was also associated with increased all-cause and cardiovascular mortality [17, 27, 28]. The clinical significance of these findings is difficult to generalize because in the past, diagnostic criteria for orthostatic were not harmonized.
Diagnosing orthostatic hypertension
When diagnosing an exaggerated orthostatic pressor response or orthostatic hypertension, blood pressure measurements with a brachial cuff suffice. Pulse rate should also be recorded. Preferably, measurements should be conducted in a quiet surrounding to limit confounding of orthostatic blood pressure responses by external stimuli. Supine blood pressure and heart rate should be measured after five minutes of rest in the supine position. Then, patients should stand up actively. Upright blood pressure and heart rate should be measured after 1, 3, and 5 min, at least, to confirm the persistent character of the blood pressure change. We suggest that the measurements after 3 and 5 min be averaged to determine standing systolic blood pressure. For screening purposes, a single measurement after 3 min may be sufficient.
Beat-to-beat blood pressure and heart rate recordings can be applied in selected patients but are not widely available [8].
We recommend that repeated orthostatic testing should be conducted on a different day to confirm the diagnosis.
Because supine and upright blood pressure measurements may be difficult to conduct in all patients, seated to upright measurements may be considered for screening purposes. Since hemodynamic changes when standing up from the seated standing position are less compared with standing up from the supine position, the orthostatic pressor response may be less pronounced such that the sensitivity in detecting orthostatic hypertension may decrease. Similar limitations have been observed when using seated to standing measurements when diagnosing orthostatic hypotension [29]. Therefore, we suggest that confirmatory testing be considered with supine to standing measurements.
Head-up tilt testing may be considered for persons unable to undergo an active standing test.
Clinical management
There is no evidence that individuals with an exaggerated orthostatic pressor response and blood pressure within the normal range require antihypertensive therapy. It may be prudent to follow up these patients’ blood pressure given the increased risk for progression to arterial hypertension. In patients with isolated orthostatic hypertension in whom blood pressure is only in the hypertensive range while standing, ambulatory blood pressure monitoring may have utility in gauging the overall blood pressure load during the day and detecting abnormalities in diurnal blood pressure patterns, such as extreme blood pressure dipping during the night or masked morning hypertension [2, 14]. Patients fulfilling orthostatic hypertension criteria have not been specifically sought for or excluded from blood pressure trials. It appears reasonable prescribing antihypertensive therapies according to current hypertension guidelines [3,4,5]. There is no evidence that patients with orthostatic hypertension benefit from a particular drug class in terms of cardiovascular risk protection. Whether diuretics, which could further increase neurohumoral activation while standing should be avoided in patients with orthostatic hypertension is unclear given the known benefits of such drugs on cardiovascular morbidity and mortality. Overall, there is a need for additional research to guide clinical decision making in patients with an exaggerated orthostatic pressor response and orthostatic hypertension. We hope that a uniform definition will support this endeavor.
References
Jordan J, Ricci F, Hoffmann F, Hamrefors V, Fedorowski A. Orthostatic hypertension: critical appraisal of an overlooked condition. Hypertension. 2020;75:1151–8.
Kario K. Orthostatic hypertension–a new haemodynamic cardiovascular risk factor. Nat Rev Nephrol. 2013;9:726–38.
Whelton PK, Carey RM, Aronow WS, Casey DE Jr., Collins KJ, Dennison Himmelfarb C, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Hypertension. 2018;71:e127–e248.
Williams B, Mancia G, Spiering W, Agabiti Rosei E, Azizi M, Burnier M, et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension. J Hypertens. 2018;36:1953–2041.
Umemura S, Arima H, Arima S, Asayama K, Dohi Y, Hirooka Y, et al. The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2019). Hypertens Res. 2019;42:1235–481.
Fedorowski A, Stavenow L, Hedblad B, Berglund G, Nilsson PM, Melander O. Orthostatic hypotension predicts all-cause mortality and coronary events in middle-aged individuals (The Malmo Preventive Project). Eur Heart J. 2010;31:85–91.
Brunkwall L, Jönsson D, Ericson U, Hellstrand S, Kennbäck C, Östling G, et al. The Malmö Offspring Study (MOS): design, methods and first results. Eur J Epidemiol. 2021;36:103–16.
Finucane C, van Wijnen VK, Fan CW, Soraghan C, Byrne L, Westerhof BE, et al. A practical guide to active stand testing and analysis using continuous beat-to-beat non-invasive blood pressure monitoring. Clin Auton Res. 2019;29:427–41.
Komori T, Eguchi K, Kario K. The measurement of orthostatic blood pressure as a screening tool for masked hypertension with abnormal circadian blood pressure rhythm. Hypertens Res. 2016;39:631–2.
Jordan J, Shannon JR, Black BK, Lance RH, Squillante MD, Costa F, et al. NN-nicotinic blockade as an acute human model of autonomic failure. Hypertension. 1998;31:1178–84.
Freeman R, Abuzinadah AR, Gibbons C, Jones P, Miglis MG, Sinn DI. Orthostatic hypotension: JACC state-of-the-art review. J Am Coll Cardiol. 2018;72:1294–309.
Streeten DH, Auchincloss-JH J, Anderson-GH J, Richardson RL, Thomas FD, Miller JW. Orthostatic hypertension. Pathogenetic Stud Hypertension. 1985;7:196–203.
Vriz O, Soon G, Lu H, Weder AB, Canali C, Palatini P. Does orthostatic testing have any role in the evaluation of the young subject with mild hypertension?: an insight from the HARVEST study. Am J Hypertens. 1997;10:546–51.
Kario K, Eguchi K, Nakagawa Y, Motai K, Shimada K. Relationship between extreme dippers and orthostatic hypertension in elderly hypertensive patients. Hypertension. 1998;31:77–82.
Kario K, Eguchi K, Hoshide S, Hoshide Y, Umeda Y, Mitsuhashi T, et al. U-curve relationship between orthostatic blood pressure change and silent cerebrovascular disease in elderly hypertensives: orthostatic hypertension as a new cardiovascular risk factor. J Am Coll Cardiol. 2002;40:133–41.
Hoshide S, Parati G, Matsui Y, Shibazaki S, Eguchi K, Kario K. Orthostatic hypertension: home blood pressure monitoring for detection and assessment of treatment with doxazosin. Hypertens Res. 2012;35:100–6.
Kostis WJ, Sargsyan D, Mekkaoui C, Moreyra AE, Cabrera J, Cosgrove NM, et al. Association of orthostatic hypertension with mortality in the Systolic Hypertension in the Elderly Program. J Hum hypertension. 2019;33:735–40.
Nardo CJ, Chambless LE, Light KC, Rosamond WD, Sharrett AR, Tell GS, et al. Descriptive epidemiology of blood pressure response to change in body position. The ARIC study. Hypertension. 1999;33:1123–9.
Fedorowski A, Ostling G, Persson M, Struck J, Engstrom G, Nilsson PM, et al. Orthostatic blood pressure response, carotid intima-media thickness, and plasma fibrinogen in older nondiabetic adults. J Hypertens. 2012;30:522–9.
Fleg JL, Evans GW, Margolis KL, Barzilay J, Basile JN, Bigger JT, et al. Orthostatic hypotension in the ACCORD (Action to Control Cardiovascular Risk in Diabetes) Blood Pressure Trial: prevalence, incidence, and prognostic significance. Hypertension. 2016;68:888–95.
Townsend RR, Chang TI, Cohen DL, Cushman WC, Evans GW, Glasser SP, et al. Orthostatic changes in systolic blood pressure among SPRINT participants at baseline. J Am Soc Hypertension. 2016;10:847–56.
Yoshinari M, Wakisaka M, Nakamura U, Yoshioka M, Uchizono Y, Iwase M. Orthostatic hypertension in patients with type 2 diabetes. Diabetes Care. 2001;24:1783–6.
Thomas RJ, Liu K, Jacobs DR Jr, Bild DE, Kiefe CI, Hulley SB. Positional change in blood pressure and 8-year risk of hypertension: the CARDIA Study. Mayo Clin Proc. 2003;78:951–8.
Fan XH, Wang Y, Sun K, Zhang W, Wang H, Wu H, et al. Disorders of orthostatic blood pressure response are associated with cardiovascular disease and target organ damage in hypertensive patients. Am J Hypertens. 2010;23:829–37.
Juraschek SP, Daya N, Appel LJ, Miller ER III, McEvoy JW, Matsushita K, et al. Orthostatic hypotension and risk of clinical and subclinical cardiovascular disease in middle-aged adults. J Am Heart Assoc. 2018;7:e008884.
Yatsuya H, Folsom AR, Alonso A, Gottesman RF, Rose KM. Postural changes in blood pressure and incidence of ischemic stroke subtypes: the ARIC study. Hypertension. 2011;57:167–73.
Veronese N, De Rui M, Bolzetta F, Zambon S, Corti MC, Baggio G, et al. Orthostatic changes in blood pressure and mortality in the elderly: the Pro.V.A Study. Am J Hypertens. 2015;28:1248–56.
Agnoletti D, Valbusa F, Labat C, Gautier S, Mourad JJ, Benetos A. Evidence for a prognostic role of orthostatic hypertension on survival in a very old institutionalized population. Hypertension. 2016;67:191–6.
Breeuwsma AC, Hartog LC, Kamper AM, Groenier KH, Bilo HJ, Kleefstra N, et al. Standing orthostatic blood pressure measurements cannot be replaced by sitting measurements. Hypertens Res. 2017;40:765–770.
Author information
Authors and Affiliations
Corresponding authors
Ethics declarations
Conflict of interest
JJ served as an advisor for Novo-Nordisk and Bayer, received research support from Boehringer Ingelheim and Novo-Nordisk, and is co-founder of Eternygen GmbH. He is the Editor-in-Chief of Clinical Autonomic Research and International Associate Editor of Hypertension Research but was not involved in the editorial handling of this manuscript. IB is a consultant for Theravance Biopharma, Takeda Inc., and Amneal Pharmaceuticals, and has a patent for an automated abdominal binder to treat orthostatic hypotension. He is supported by NIH grants R01HL149386 and R01HL161095. VK, PN, GG, and AF report no conflicts of interest. KK is the Editor-in-Chief of Hypertension Research but was not involved in the editorial handling of this manuscript.
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
This article is co-published in the journals Hypertension Research and Clinical Autonomic Research, https://doi.org/10.1038/s41440-022-01074-0 or https://doi.org/10.1007/s10286-022-00897-8.
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Jordan, J., Biaggioni, I., Kotsis, V. et al. Consensus statement on the definition of orthostatic hypertension endorsed by the American Autonomic Society and the Japanese Society of Hypertension. Hypertens Res 46, 291–294 (2023). https://doi.org/10.1038/s41440-022-01074-0
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41440-022-01074-0
Keywords
This article is cited by
-
Cardiovascular autonomic dysfunction in post-COVID-19 syndrome: a major health-care burden
Nature Reviews Cardiology (2024)
-
Orthostatic hypertension—too much of a good thing
Clinical Autonomic Research (2023)
-
Raising awareness for cardiovascular autonomic dysfunction: the 2023 European Society of Hypertension guidelines revisited
Clinical Autonomic Research (2023)